Advanced Chinese Medicine最新文献

筛选
英文 中文
Treatment of primary cutaneous CD30-positive anaplastic large cell lymphoma with Wenyang Shengji decoction and Huanglian ointment: A case report 温阳生肌汤加黄连软膏治疗原发性皮肤 CD30 阳性无细胞大细胞淋巴瘤:病例报告
Advanced Chinese Medicine Pub Date : 2024-11-20 DOI: 10.1002/acm4.27
Kai Li, Tingting Bao, Ruonan Wei, Yingying Yang, Mengjiao Kang, Wei Zhang, Xianyu Zeng, Yiqun Duan, Liuqing Chen, Linhua Zhao
{"title":"Treatment of primary cutaneous CD30-positive anaplastic large cell lymphoma with Wenyang Shengji decoction and Huanglian ointment: A case report","authors":"Kai Li,&nbsp;Tingting Bao,&nbsp;Ruonan Wei,&nbsp;Yingying Yang,&nbsp;Mengjiao Kang,&nbsp;Wei Zhang,&nbsp;Xianyu Zeng,&nbsp;Yiqun Duan,&nbsp;Liuqing Chen,&nbsp;Linhua Zhao","doi":"10.1002/acm4.27","DOIUrl":"https://doi.org/10.1002/acm4.27","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Primary cutaneous CD30 positive anaplastic large cell lymphoma (PC-ALCL) is a rare non-Hodgkin's lymphoma. Combined chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), or F-MACHOP (5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone) are often used for its clinical treatment. In this study, we reported a new treatment method using a traditional Chinese therapy involving oral <i>Wenyang Shengji decoction</i> (WSD) combined with <i>Huanglian ointment</i> applied externally in a 32-year-old female patient with PC-ALCL. Introduction: A 32-year-old woman who complained of an ulcer on the forehead accompanied by significant pain. PC-ALCL was diagnosed by histopathological examination and immunohistochemical analysis. Treatment plan: WSD was prepared in 300 mL water and administered orally as a 150 mL decoction twice daily, and <i>Huanglian ointment</i> was applied to the ulcer three times daily. After 8 weeks of treatment with WSD combined with <i>Huanglian ointment</i>, the lesion healed completely. Immunohistochemical analysis revealed the presence of scattered CD3+++, CD4++, CD8++, CD20++, and CD30-positive cells. After 12 weeks of treatment, the ulcer healed completely, leaving only a marked pale red-pitted scar. The patient was followed up for 3 years without recurrence and no adverse events. Conclusion: oral WSD combined with <i>Huanglian ointment</i> applied to the ulcer for PC-ALCL can promote the healing of ulcers, reduce or alleviate the formation of scar, and eliminate CD30-positive cells. This case report provides a reference for the clinical treatment of PC-ALCL using traditional Chinese medicine.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 3","pages":"172-178"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.27","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in the application of cardiopulmonary exercise testing for overweight and obese populations 超重和肥胖人群心肺运动测试的应用进展
Advanced Chinese Medicine Pub Date : 2024-10-17 DOI: 10.1002/acm4.26
Tingshuai Fu, Mingzhong Xiao, Jiajia Ding, Chenxia Lu, Peiran Wang, Jingjing Yang, Qing Zhang
{"title":"Advancements in the application of cardiopulmonary exercise testing for overweight and obese populations","authors":"Tingshuai Fu,&nbsp;Mingzhong Xiao,&nbsp;Jiajia Ding,&nbsp;Chenxia Lu,&nbsp;Peiran Wang,&nbsp;Jingjing Yang,&nbsp;Qing Zhang","doi":"10.1002/acm4.26","DOIUrl":"https://doi.org/10.1002/acm4.26","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the advancements in cardiopulmonary exercise testing (CPET) among overweight or obese patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Reviewed the recent studies on clinical trials of CPET in overweight and obese patients, thought about the CPET advantage in obesity, while CPET equipment use for elucidating the principles underlying obesity and using CPET kinematic scheme to explore fat metabolism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The exercise program developed by CPET is scientific, sustainable and advantageous. With this trial, we can develop a relatively effective, fast and measurable amount of exercise, on the basis of the exercise test in obese people, CPET can provide scientific and digital motion reducing weight for overweight patients. At the same time, the trial has become widely applied in research into drug and surgical treatments for overweight patients. It is possible to quantify the efficacy of a trial and ultimately assess the merits of CPET.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>CPET is considered as a fundamental criterion for designing motion schemes. Despite limitations of equipment errors and patient endurance, the benefits of CPET in program formulation have been gradually recognized, which made it a promising tool in the field of obesity management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 3","pages":"162-171"},"PeriodicalIF":0.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.26","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates of surgical treatment in hemorrhoidal disease 痔疮手术治疗的最新进展
Advanced Chinese Medicine Pub Date : 2024-08-29 DOI: 10.1002/acm4.25
Jianan Li, Huangfu Ma, Yue Wang, Lixia Lai, Xuecheng Zhang, Yanmei Wang
{"title":"Updates of surgical treatment in hemorrhoidal disease","authors":"Jianan Li,&nbsp;Huangfu Ma,&nbsp;Yue Wang,&nbsp;Lixia Lai,&nbsp;Xuecheng Zhang,&nbsp;Yanmei Wang","doi":"10.1002/acm4.25","DOIUrl":"https://doi.org/10.1002/acm4.25","url":null,"abstract":"<p>Hemorrhoidal disease is one of the most prevalent and frequently occurring conditions worldwide. Treatment modalities for hemorrhoids are multifaceted and tailored according to the severity of the condition. Various surgical procedures and modified approaches had been invented since 1937. Here we review the workflow, advantages, and disadvantages of different types of hemorrhoid surgery (conventional excisional hemorrhoidectomy, modified excisional surgery, stapled/partial stapled hemorrhoidopexy, and Doppler-guided hemorrhoidal artery ligation). There is no single treatment that fits all hemorrhoid patients. Surgeons should make the operation plan based on patients' conditions and wills.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 3","pages":"156-161"},"PeriodicalIF":0.0,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert consensus on quality control indicators for integrative medicine in ankylosing spondylitis (2023 version) 强直性脊柱炎中西医结合治疗质量控制指标专家共识(2023 年版)
Advanced Chinese Medicine Pub Date : 2024-08-14 DOI: 10.1002/acm4.24
Qingwen Tao, Liubo Zhang, Zeran Yan, Weiping Kong, Yuan Xu, Nan Zhang
{"title":"Expert consensus on quality control indicators for integrative medicine in ankylosing spondylitis (2023 version)","authors":"Qingwen Tao,&nbsp;Liubo Zhang,&nbsp;Zeran Yan,&nbsp;Weiping Kong,&nbsp;Yuan Xu,&nbsp;Nan Zhang","doi":"10.1002/acm4.24","DOIUrl":"https://doi.org/10.1002/acm4.24","url":null,"abstract":"<p>The integrated treatment with Chinese and Western medicine plays an important role in the treatment of ankylosing spondylitis (AS), which can significantly relieve the patient's symptoms and improve quality of life. However, as a result of the lack of standardization of clinical management in some regions, the quality of AS treatment in China remains unoptimistic. In 2021, initiated by the Center for Integrative Medicine of China-Japan Friendship Hospital, led by the traditional Chinese medicine department of rheumatology of China-Japan Friendship Hospital, relying on the rheumatology branch of the Beijing Association of the integrating of traditional and Western medicine, and using the Delphi method, an expert consensus on “Quality Control Indicators for Integrative Medicine in Ankylosing Spondylitis” was established (Beijing Association of the Integrating of Traditional and Western Medicine Standardization Expert Consensus Filing Number: 2021Z031A2). The consensus revision updates the 2021 version by adding four items, which will provide a reference for the quality control of integrated traditional Chinese and Western medicine for AS in China and help improve the current diagnosis and treatment status of AS.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 3","pages":"149-155"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.24","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical application of traditional Chinese medicine in the treatment of neuroendocrine neoplasms 中药治疗神经内分泌肿瘤的临床应用
Advanced Chinese Medicine Pub Date : 2024-07-16 DOI: 10.1002/acm4.23
Ying-Ying Chen, Shao-Bo Hu, Fei Su, Fu-Huan Yu, Ru-Ao Chen, Zi-Xuan Cheng, Huang-Ying Tan
{"title":"Clinical application of traditional Chinese medicine in the treatment of neuroendocrine neoplasms","authors":"Ying-Ying Chen,&nbsp;Shao-Bo Hu,&nbsp;Fei Su,&nbsp;Fu-Huan Yu,&nbsp;Ru-Ao Chen,&nbsp;Zi-Xuan Cheng,&nbsp;Huang-Ying Tan","doi":"10.1002/acm4.23","DOIUrl":"10.1002/acm4.23","url":null,"abstract":"<p>Neuroendocrine neoplasms (NENs) are a group of rare tumors with strong heterogeneity. Among these tumors, well-differentiated tumors can have a relatively good survival prognosis, while some tumors can have strong malignant potential and lead to increased mortality. Traditional Chinese medicine (TCM), which has a long history of thousands of years, has been widely used to treat tumors due to its unique advantages, such as economy, efficacy and few side effects. In recent years, the role of TCM in the treatment of NENs has gradually emerged. It can not only help prevent tumor recurrence and reduce the side effects of radiotherapy and chemotherapy but also relieve symptoms and improve quality of life. Various clinical studies have indicated that TCM has achieved good curative effects at different stages of treatment. We summarized the last 10 years of research progress on the clinical application of TCM in the treatment of NENs from four points of entry, aiming to provide a reference for the treatment of NENs.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 3","pages":"144-148"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141832080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert consensus on quality control indicators for integrative medicine in rheumatoid arthritis (2023 version) 类风湿性关节炎综合疗法质量控制指标专家共识(2023 年版)
Advanced Chinese Medicine Pub Date : 2024-07-08 DOI: 10.1002/acm4.13
Qingwen Tao, Jinping Wang, Zihan Wang, Yuan Xu, Jianming Wang, Yingze Zhang
{"title":"Expert consensus on quality control indicators for integrative medicine in rheumatoid arthritis (2023 version)","authors":"Qingwen Tao,&nbsp;Jinping Wang,&nbsp;Zihan Wang,&nbsp;Yuan Xu,&nbsp;Jianming Wang,&nbsp;Yingze Zhang","doi":"10.1002/acm4.13","DOIUrl":"https://doi.org/10.1002/acm4.13","url":null,"abstract":"<p>The rising costs of cancer care and subsequent medical financial hardship for cancer survivors and families are well documented in the United States. Less attention has been paid to employment disruptions and loss of household income after a cancer diagnosis and during treatment, potentially resulting in lasting financial hardship, particularly for working-age adults not yet age-eligible for Medicare coverage and their families. In this article, the authors use a composite patient case to illustrate the adverse consequences of cancer diagnosis and treatment for employment, health insurance coverage, household income, and other aspects of financial hardship. They summarize existing research and provide nationally representative estimates of multiple aspects of financial hardship and health insurance coverage, benefit design, and employee benefits, such as paid sick leave, among working-age adults with a history of cancer and compare them with estimates among working-age adults without a history of cancer from the most recently available years of the National Health Interview Survey (2019–2021). Then, the authors identify opportunities for addressing employment and health insurance coverage challenges at multiple levels, including federal, state, and local policies; employers; cancer care delivery organizations; and nonprofit organizations. These efforts, when informed by research to identify best practices, can potentially help mitigate the financial hardship associated with cancer.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 2","pages":"79-86"},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141624334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative therapy of traditional Chinese medicine and conventional medicine in the treatment of lupus nephritis from a single-center experience 从单中心经验看治疗狼疮性肾炎的中西医结合疗法
Advanced Chinese Medicine Pub Date : 2024-07-07 DOI: 10.1002/acm4.22
Ruihua Liu, Xiao Yang, Jianwen Yu, Qiong Wen, Xueqing Yu, Wei Chen
{"title":"Integrative therapy of traditional Chinese medicine and conventional medicine in the treatment of lupus nephritis from a single-center experience","authors":"Ruihua Liu,&nbsp;Xiao Yang,&nbsp;Jianwen Yu,&nbsp;Qiong Wen,&nbsp;Xueqing Yu,&nbsp;Wei Chen","doi":"10.1002/acm4.22","DOIUrl":"10.1002/acm4.22","url":null,"abstract":"<p>Lupus nephritis (LN) is the most common complication of systemic lupus erythematosus and the leading cause of mortality. The complex pathogenesis and various clinical manifestations of this disease increase the difficulty of the treatments. The current treatments with Western medicine including glucocorticoids, mycophenolate mofetil and other immunosuppressants, and biological agents have greatly improved the patients' survival. However, frequent recurrence occurred and LN remained an important cause of end stage renal disease. The increasing adverse effects with the prolongation of treatment also restrained the efficacy of Western medicine. Increasing evidence has demonstrated the therapeutic efficacy of traditional Chinese medicine (TCM) which provides a theoretical basis for the integrative therapy of TCM and Western medicine for LN. We previously established a unique comprehensive treatment strategy for LN with the combination of TCM and Western medicine based on the TCM theory and achieved good clinical efficacy. This review will summarize the single-center experience that integrative therapy of TCM, represented by Lupus Recipe and artesunate, and Western medicine for LN treatment, and elucidate the potential mechanism, with the purpose to provide reliable evidence for developing more effective personalized treatment strategies in the future.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 3","pages":"137-143"},"PeriodicalIF":0.0,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.22","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141671134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study to evaluate the effect of Tangshen Fang combined with guideline-directed medical treatment on the quality of life and clinical outcomes in patients with diabetic nephropathy: A clinical trial on constructing a novel paradigm of integrated traditional Chinese and Western medicine in the treatment of diabetic nephropathy 糖尿病肾病患者生活质量和临床疗效的中西医结合治疗新模式的临床试验:构建中西医结合治疗糖尿病肾病新模式的临床试验
Advanced Chinese Medicine Pub Date : 2024-06-20 DOI: 10.1002/acm4.19
Xian Jin, Yanmei Wang, Ping Li, Lili Wu, Na Wang, Jun Duan, Qinyu Jiang, Yangxi Li, Zhuo Yin, Xi'ai Wu, Xiaoping Chen
{"title":"Study to evaluate the effect of Tangshen Fang combined with guideline-directed medical treatment on the quality of life and clinical outcomes in patients with diabetic nephropathy: A clinical trial on constructing a novel paradigm of integrated traditional Chinese and Western medicine in the treatment of diabetic nephropathy","authors":"Xian Jin,&nbsp;Yanmei Wang,&nbsp;Ping Li,&nbsp;Lili Wu,&nbsp;Na Wang,&nbsp;Jun Duan,&nbsp;Qinyu Jiang,&nbsp;Yangxi Li,&nbsp;Zhuo Yin,&nbsp;Xi'ai Wu,&nbsp;Xiaoping Chen","doi":"10.1002/acm4.19","DOIUrl":"https://doi.org/10.1002/acm4.19","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes mellitus and has become the primary cause of end-stage renal disease in China. In patients with severe renal insufficiency, Western medical treatments often yield unsatisfactory results. Preliminary studies have indicated that the Chinese herbal formula Tangshen Fang improves estimated glomerular filtration rate (eGFR) in patients with DKD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods/design</h3>\u0000 \u0000 <p>This is a multicenter, randomized, open-label, controlled clinical trial. DKD patients with eGFR levels between 25 and 75 mL/min (1.73 m<sup>2</sup>) and urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g, or eGFR level between 25 and 60 mL/min (1.73 m<sup>2</sup>) and UACR &lt;30 mg will be included. A total of 144 participants will be randomly allocated to the treatment group (Tangshen Fang plus standard Western medicine with or without other traditional Chinese medicine [TCM]) and the control group (standard Western medicine with or without other TCM) at a 1:1 ration. The study duration will be 24 weeks and the follow-up period will be extended to 96 weeks. The primary endpoint will be the change in eGFR from baseline to week 24. Secondary endpoints will include changes in UACR, body weight, waist circumference, blood pressure, lipid levels, fasting plasma glucose, glycosylated hemoglobin A<sub>1</sub>c (HbA<sub>1</sub>c), and improvement in TCM symptoms and quality of life. Adverse events will also be evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This study will provide evidence of the effectiveness and safety of Tangshen Fang in treating patients with DKD. It will also form the clinical pathway and expert consensus on integrating traditional Chinese and Western medicine for DKD and provide clinical evidence for the rational use of hospital preparations of Tangshen Fang.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial registration</h3>\u0000 \u0000 <p>Chinese Clinical Trials Registry, ChiCTR2300069269. Registered March 10, 2023.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 2","pages":"105-113"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141624259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilizing data mining techniques to analyze traditional Chinese medicine patterns in patients with acute cardiorenal syndrome 利用数据挖掘技术分析急性心肾综合征患者的中医模式
Advanced Chinese Medicine Pub Date : 2024-06-20 DOI: 10.1002/acm4.14
Deshuang Yang, Jiangquan Liao, Shiyi Tao, Ziyi Sun, Li Huang, Xiang Xiao, Fang Wang, Mingjing Shao
{"title":"Utilizing data mining techniques to analyze traditional Chinese medicine patterns in patients with acute cardiorenal syndrome","authors":"Deshuang Yang,&nbsp;Jiangquan Liao,&nbsp;Shiyi Tao,&nbsp;Ziyi Sun,&nbsp;Li Huang,&nbsp;Xiang Xiao,&nbsp;Fang Wang,&nbsp;Mingjing Shao","doi":"10.1002/acm4.14","DOIUrl":"https://doi.org/10.1002/acm4.14","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study intends to investigate the medication patterns of traditional Chinese medicine (TCM) for the treatment of acute cardiorenal syndrome (ACRS) through clinical data mining.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective study was conducted at China-Japan Friendship Hospital, encompassing hospitalized patients with ACSR admitted from June 1, 2013, to June 30, 2022. Patient treatment records, including TCM prescriptions, were gathered to establish a comprehensive prescription database. The prescriptions underwent analysis using the ancient and modern medical case cloud platform, incorporating the frequency, properties and flavors and channel tropism of each herbs, and clustering patterns, combination relationships, and complex network analysis of the whole.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 330 prescriptions from eligible hospitalized patients were included, which totally involves 324 kinds of different herbs. The therapeutic effects primarily emphasized descending qi and eliminating turbidity, promoting diuresis and reducing swelling, drying dampness and dispelling phlegm, and promoting the ascension of Yang Qi. The properties were largely warm, netural, slightly cool and cold, with warm being predominant. The flavors were chiefly sweet, spicy, and bitter, with sweetness being the most common. The major channel tropism were the lung and spleen meridians, followed by the stomach, liver, heart, and kidney meridians. Combination analysis identified 30 pairs of combinations, with higher associations found in combinations such as Jiegeng, Huangqi, Chaihu, Baizhu, Zhimu, and Dangshen. Cluster analysis categorized high-frequency herbs into 4 groups: Gualou–Fabanxia–Chuanxiong–Chishao, Fuling–Baizhu–Zhigancao–Chenpi, Maidong–Guizhi–Huangqi–Chaihu–Shengma–Zhimu–Shanzhuyu, and Huangqi–Dangshen–Jiegeng–Chaihu–Shengma–Zhimu–Shanzhuyu. Complex network analysis revealed core prescriptions for treating ACRS, including 17 herbs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In the treatment of ACRS, TCM herbs with the properties of warm and neturality, and the flavors of sweet and spicy are commonly utilized. The prescribed herbal formulas have the effect of descending qi and eliminating turbidity, tonifying qi, activating blood and resolving stasis, resolving phlegm and promoting water.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 2","pages":"114-127"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141624260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined application of the traditional Chinese herbal medicine, Renvatinib, and Carrelizumab in a patient with primary liver cancer: A case report and literature review 在一名原发性肝癌患者身上联合应用中药瑞伐替尼和卡瑞珠单抗:病例报告和文献综述
Advanced Chinese Medicine Pub Date : 2024-06-20 DOI: 10.1002/acm4.20
Yan Zhu, Yaoshui Lai, Hongjie Song
{"title":"Combined application of the traditional Chinese herbal medicine, Renvatinib, and Carrelizumab in a patient with primary liver cancer: A case report and literature review","authors":"Yan Zhu,&nbsp;Yaoshui Lai,&nbsp;Hongjie Song","doi":"10.1002/acm4.20","DOIUrl":"https://doi.org/10.1002/acm4.20","url":null,"abstract":"<p>The patient was diagnosed with primary liver cancer featuring intrahepatic metastasis (Barcelona stage B; Stage IIB), hepatitis B infection, and post-hepatitis B cirrhosis during the period of compensated liver function. Following a 7-month regimen combining traditional Chinese herbal medicine (TCHM) with Renvatinib and Carrelizumab, the patient exhibited favorable tolerability, no bleeding risks, and stable tumor progression. The effectiveness of TCHM in this case was marked by significant symptom alleviation, reduced serum molecular markers, minimized adverse reactions, and obviated surgical intervention. Blood tests displayed alpha-fetoprotein levels ranging from 8.85 to 20.65 IU/mL, with no increase in bleeding risks.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 2","pages":"128-135"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141624573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信